Journal papers and conference posters

 

 

HPA CDR-Weekly publications are listed under the Epidemiological data section of the website.

 

2005

 

• Mushtaq S, et al.  In-Vitro Interactions of Doripenem With Other Antibacterial Agents (PDF, 162 KB)
  45th ICAAC conference; 2005 Dec; Washington, US.
  
  
• Livermore DM, et al. Selectivity of ertapenem for P. aeruginosa mutants cross-resistant to other carbapenems.   J. Antimicrob. Chemother. 2005 Mar; 55(3):306-11.

 

2004

 

• Crespo MP, et al. Outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-8, a novel metallo-b-lactamase, in a tertiary care centre in Cali, Colombia. J. Clin. Microbiol. 2004 Nov; 42(11):5094-101.
• Mushtaq S, et al. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob. Agents Chemother. 2004 Aug; 48(8):3086-92.
• Scott FW, et al. Identification and characterization of transmissible Pseudomonas aeruginosa strains in cystic fibrosis patients in England and Wales. J. Med. Microbiol. 2004 Jul; 53(Pt 7):609-15. .
• Reynolds R, et al. Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance Programme. J. Antimicrob. Chemother.  2004 Jun; 53(6):1018-32.

 

2003

 

• Mushtaq S, et al. Activity of Doripenem vs Pseudomonas aeruginosa Isolates, Mutants, and Transconjugants with Defined Resistance Phenotype [poster] (PDF, 188 KB)
  43rd ICAAC conference; 2003 Sept; Chicago, US.
  
  
• Woodford N, et al. Emergence of pseudomonas with VIM-type carbapenemases in the United Kingdom [poster]. (PDF, 233 KB)
  43rd ICAAC conference; 2003 Sept; Chicago, US.
  
  
• Woodford, et al. Outbreak of pseudomonas producing a VIM-type carbapenemase in a tertiary hospital in Cali, Colombia [poster] (PDF, 148 KB)
  43rd ICAAC conference; 2003 Sept; Chicago, US.
  
     
• Livermore DM. The threat from the pink corner. Ann. Med. 2003; 35(4):226-34.

 

2002

 

• Pitt TL. Cross infection of cystic fibrosis with Pseudomonas aeruginosa. Thorax 2002 Nov; 57(11):921.
• Lee K, et al. blaVIM-2 cassettte-containing novel integrons in metallo-b-lactamase-producing   Pseudomonas aeruginosa and Pseudomonas putida isolates disseminated in a Korean hospital. Antimicrob. Agents Chemother.  2002 Apr; 46(4):1053-8.
• Livermore DM. Multiple mechanisms of anitmicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?  Clin. Infect. Dis.  2002 Mar 1; 34(5):634-40.
• Livermore DM. The impact of carbapenemases on antimicrobial development and therapy. Curr. Opin. Investigat. Drugs.  2002 Feb; 3(2):218-24.
• Gibb AP, et al. Nosocomial outbreak of carbapenem-resistant Pseudomonas aeruginosa with a new blaIMP allele, blaIMP-7. Antimicrob. Agents Chemother.  2002 Jan;46(1):255-8.